Marshak Richard 4

What Happened
Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences (TLSI), disposed of a total of 3,457 shares across three transactions in March 2026 for aggregate proceeds of about $14,209. Breakdown: 1,449 shares on 2026-03-11 at $4.13 ($5,984); 1,589 shares on 2026-03-12 at $4.09 ($6,499); and 419 shares on 2026-03-16 at $4.12 ($1,726). These were sales (S) recorded as tax‑withholding transactions tied to the vesting of restricted stock units, not a discretionary sell decision.

Key Details

• Transaction dates and prices:
  • 2026-03-11: 1,449 shares @ $4.13 = $5,984
  • 2026-03-12: 1,589 shares @ $4.09 = $6,499
  • 2026-03-16: 419 shares @ $4.12 = $1,726
• Total: 3,457 shares sold for ≈ $14,209.
• Shares owned after transaction: Not disclosed in the provided filing.
• Footnote F1: Sales were to satisfy tax withholding obligations on vested restricted stock units — this is a non‑discretionary, routine tax withholding sale.
• Filing: Form 4 filed 2026-03-20 reporting transactions from 2026-03-11 to 2026-03-16; this appears later than the SEC’s standard two-business-day Form 4 filing window.

Context
Sales reported as tax withholding for vested RSUs are routine and generally do not signal an insider’s change in view about the company. For retail investors, purchases by insiders tend to be more informative about confidence; this filing documents a modest, routine liquidity event rather than a new investment or strategic move.